52121-34-3

Basic information

• Product Name: 2-broMo-1-ethyl-4-nitrobenzene
• Synonyms: 2-broMo-1-ethyl-4-nitrobenzene
• CAS NO: 52121-34-3
• Molecular Formula: C₈H₈BrNO₂
• Molecular Weight: 230.05862
• EINECS: -0
• Mol File: 52121-34-3.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-broMo-1-ethyl-4-nitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-broMo-1-ethyl-4-nitrobenzene(52121-34-3)
• EPA Substance Registry System: 2-broMo-1-ethyl-4-nitrobenzene(52121-34-3)

Safety Data

• Hazardous Substances Data: 52121-34-3(Hazardous Substances Data)

Usage

General Description

2-Bromo-1-ethyl-4-nitrobenzene is a chemical compound with the molecular formula C8H8BrNO2. It is a nitrobenzene derivative with a bromine and an ethyl group attached to the benzene ring. 2-broMo-1-ethyl-4-nitrobenzene is primarily used as a building block in the synthesis of various pharmaceuticals, agrochemicals, and organic compounds. It is also used as an intermediate in the production of dyes, pigments, and other industrial chemicals. 2-Bromo-1-ethyl-4-nitrobenzene is a yellowish crystalline solid with a slightly oily texture and a distinctive aromatic odor. It is important to handle this compound with caution, as it is toxic and may cause skin and eye irritation upon contact.

Upstream product

• 100-12-9 4-ethylnitrobenzene 
• 77-48-5 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione 
• 20191-74-6 2-ethyl-5-nitroaniline 

Downstream Products

• 90004-93-6 2-bromo-4-nitroacetophenone 
• 52121-36-5 3-bromo-4-ethylphenylamine 
• 878487-84-4 α-(2-ethyl-5-methoxyphenyl)acetophenone 
• 540495-28-1 4-ethyl-3-bromo-phenol 
• 852946-96-4 2-bromo-1-ethyl-4-methoxybenzene 
• 38678-86-3 2-bromine-4-ethylaniline 
• 1445789-74-1 C₃₁H₃₃N₅O₅ 
• 1445789-70-7 methyl 3-(7-bromo-3-carbamoyl-6-ethylquinolin-4-ylamino)-5-cyclopentylbenzoate 
• 1445789-64-9 diethyl 2-((3-bromo-4-ethylphenylamino)methylene)malonate 
• 1445786-78-6 3-((3-carbamoyl-7-(2,4-dimethoxypyrimidin-5-yl)-6-ethylquinolin-4-yl)amino)-5-cyclopentylbenzoic acid 
• 100876-57-1 (4-ethyl-2-nitro-5-propyl-phenyl)-carbamic acid ethyl ester 
• 99981-70-1 4-ethyl-2-nitro-5-propyl-aniline 
• 104178-22-5 4-ethyl-5-propyl-o-phenylenediamine 
• 104177-69-7 4-ethyl-3-propyl-aniline 

Relevant articles and documents

PHARMACEUTICAL COMPOSITION AND APPLICATION REPLACING QUINOLONE DERIVATIVE, PHARMACEUTICAL ACCEPTABLE SALT, OR STEREOISOMER

Provided are a substituted quinolone derivative as shown by formula (I), or a pharmaceutically acceptable salt and a prodrug molecule thereof, and a pharmaceutical composition thereof, as well as the use of same in preparing drugs for the prevention and treatment of a tumor. The quinolone derivative, salt, prodrug molecule, and pharmaceutical composition thereof can be used as a protein kinase inhibitor, which is effective in inhibiting the activity of AXL protein kinase, and is capable of inhibiting the proliferation, migration and invasion of various tumor cells; and can be used in the preparation of anti-tumor drugs, especially drugs for treating hyperproliferative diseases such as a tumor in human beings and other mammals.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.